

---

## **ASX Announcement and Media Release**

**2 February, 2005**

**SciGen Limited**

### **December Quarter Cashflow Report**

The December Quarter cashflow report for SciGen Limited ("SciGen" or the "Company") has been released to the market today.

Cash receipts from customers remain on track at S\$1.67M (S\$3.19M YTD) and approximately 3 times the value of customer receipts for the same period last year.

Growth from the September 2004 Quarter to the December 2004 Quarter remains steady, despite the previously announced interruption to supply of Sci-B-Vac<sup>TM</sup> as the Company changes manufacturing sites.

A one off payment of S\$1.23M was made during the Quarter as a licence fee payment to SciGen's principal licensor Savient Pharmaceuticals Inc. This was the final instalment for all license fees associated with sales and marketing rights for all current products licensed from Savient. Excluding this one-off payment, SciGen's cash burn was approximately S\$330k per month.

As at 31 December 2004, the Company had a cash balance of S\$5.77M.

#### **About SciGen**

SciGen Ltd is a biopharmaceutical company essentially involved in commercialising later stage research. It co-develops and markets genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biogeneric products, which can allow for faster entry into the market, as biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in gaining regulatory approval and bringing products to market

SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with offices also in Australia, USA, Korea, Vietnam, Hong Kong and Philippines and partners in India, China, Indonesia, Israel, Poland and the Netherlands.

**=====ENDS=====**

## **Media enquiries**

Mark Compton

Managing Director & CEO: Telephone: +61 2 9234 1700: Web: [www.scigen.com.au](http://www.scigen.com.au)